Pharmaceutical Executive Daily: FDA Grants Accelerated Approval to Rybrevant Faspro

Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences industry.

In today’s Pharmaceutical Executive Daily, Hims & Hers partners with Eli Lilly to sell Zepbound and Foundayo directly on its platform at self-pay prices starting at $149 a month, Novo Nordisk terminates its research collaboration with Korro Bio, and the FDA grants accelerated approval to Johnson & Johnson’s Rybrevant Faspro for previously treated head and neck cancer.

Eli Lilly and Hims & Hers entered an agreement allowing prescribed patients to access self-pay pricing for Zepbound and Foundayo directly on the Hims & Hers platform, rather than being redirected to LillyDirect. Self-pay pricing starts at $149 per month for Foundayo and $299 per month for Zepbound, with both companies committing to protect independent clinical decision-making and confirming Hims & Hers will not offer compounded copies of Lilly’s GLP-1 medicines.

Novo Nordisk terminated its research collaboration and license agreement with Korro Bio, effective February 1, 2027, ending a cardiometabolic RNA-editing partnership under which Korro earned no milestone payments. The deal had already been paused for 12 months, and Novo never nominated a second target under the original agreement’s terms.

Finally, the FDA granted accelerated approval to Johnson & Johnson’s Rybrevant Faspro, an EGFR-MET bispecific antibody, for adults with recurrent or metastatic head and neck squamous cell carcinoma that progressed after platinum-based chemotherapy and a checkpoint inhibitor. In the Phase Ib/II OrigAMI-4 trial, 102 patients showed a 42% response rate, including 15% complete responses, marking the drug’s first indication outside lung cancer.

Thanks for listening to Pharmaceutical Executive Daily. For more updates and in-depth analysis, visit PharmExec.com.